Operationalizing Bispecific Antibodies for Hematological Cancers: Insights From ASH 2025

Consolidating treatment to a single bispecific antibody for DLBCL and follicular lymphoma can improve operational efficiency and generate cost savings for oncology practices without affecting efficacy or safety.

While multi-indication bispecific therapies are likely to expand in lymphoma, their use must remain driven by efficacy, with operational efficiency and cost savings serving as added benefits rather than decision drivers.

While implementing bispecific antibodies in community oncology carries a steep learning curve, targeted education and stronger multidisciplinary collaboration can significantly improve clinician confidence and real-world uptake.

Standardized monitoring workflows and clearer reimbursement support are critical to improving community clinicians’ readiness to deliver bispecific antibodies safely in the outpatient setting.

Data suggest that remote patient monitoring may support outpatient step-up dosing of bispecific antibodies by enabling earlier CRS detection.

Remote patient monitoring can safely enable outpatient bispecific dosing for selected patients, but older or high-risk individuals may still require closer human oversight and structured support.

ASH 2025 data emphasize that standardized protocols and strong academic-community communication are essential for safe and consistent management of bispecific antibody adverse events in community oncology.

Data at ASH 2025 highlighted that standardized workflows, education, monitoring innovations, and collaboration are steadily enabling broader, safer adoption of bispecific antibodies in community oncology practice.